Biotechnology - Genomic and Proteomics/Competitive advantages in BGP: Difference between revisions
Jump to navigation
Jump to search
m (Biotechnology – Genomic and Proteomics/Competitive advantages in BGP moved to Biotechnology - Genomic and Proteomics/Competitive advantages in BGP) |
|||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{TOCright}} | |||
[[Report April 2009]] | |||
==Answer the questions:== | ==Answer the questions:== | ||
| Line 4: | Line 6: | ||
* Competitive Advantage in Biotech | * Competitive Advantage in Biotech | ||
**Only the top firms make money through sales ( | **Only the top firms make money through sales (Rosen), so the standard aspects of competitive advantage (cost leadership, differentiation, product focus, lead time, etc) do not apply to the field as a whole | ||
**Most firms therefore make their money through VC's or IPO's. For these firms, competitive advantage can be defined along the following lines: | **Most firms therefore make their money through VC's or IPO's. For these firms, competitive advantage can be defined along the following lines: | ||
***Success in initial clinical trials | ***Success in initial clinical trials | ||
***Licensing early-stage drugs for fast cash (a typical pharmaceutical company will pay US$65m for a Phase I drug. Compare with US$220m for a Phase III drug) (Hall) | ***Licensing early-stage drugs for fast cash (a typical pharmaceutical company will pay US$65m for a Phase I drug. Compare with US$220m for a Phase III drug) (Hall) | ||
***Multiple points of potential monetization in the drug development process | ***Multiple points of potential monetization in the drug development process | ||
***Proof-of-concept demonstrations | ***Proof-of-concept demonstrations | ||
***More generally, investor confidence in the possibility of bringing a drug to market | ***More generally, investor confidence in the possibility of bringing a drug to market | ||
* Barriers to Entry | * Barriers to Entry (Christoffersen) | ||
**High development costs (US$100-500m per drug) | **High development costs (US$100-500m per drug) | ||
**Long development times (10-12 years) | **Long development times (10-12 years) | ||
Latest revision as of 20:09, 19 April 2010
Answer the questions:
- Define the competitive advantages in the field and the barriers of entry
- Competitive Advantage in Biotech
- Only the top firms make money through sales (Rosen), so the standard aspects of competitive advantage (cost leadership, differentiation, product focus, lead time, etc) do not apply to the field as a whole
- Most firms therefore make their money through VC's or IPO's. For these firms, competitive advantage can be defined along the following lines:
- Success in initial clinical trials
- Licensing early-stage drugs for fast cash (a typical pharmaceutical company will pay US$65m for a Phase I drug. Compare with US$220m for a Phase III drug) (Hall)
- Multiple points of potential monetization in the drug development process
- Proof-of-concept demonstrations
- More generally, investor confidence in the possibility of bringing a drug to market
- Barriers to Entry (Christoffersen)
- High development costs (US$100-500m per drug)
- Long development times (10-12 years)
- Low probability of success (10%) makes investment less likely
- Need for highly skilled workers (Celgene, a typical large-scale Biotech firm, employs 1,287 people, 725 of whom are engaged in research)
Bibliography for Item 5 in BGP
Biotechnology_-_Genomic_and_Proteomics